Telomir Pharmaceuticals (NASDAQ: TELO) has raised approximately $5.6 million through a private investment in public equity (PIPE) financing, according to an announcement by the clinical-stage biotechnology company. The financing involved the issuance of 4,843,300 common shares at $1.16 per share, a 5% discount to the applicable 10-day volume-weighted average price.
The PIPE included an additional $1 million investment from existing significant shareholder John Paul DeJoria. Notably, the financing does not include investor warrants, convertible securities, or variable-price or reset features, which may signal favorable terms for the company and reduce potential dilution for existing shareholders.
Telomir intends to use the net proceeds primarily to support clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes. The U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for Telomir-Zn, enabling it to proceed with its first-in-human Phase 1/2 trial in patients with advanced or metastatic TNBC.
This financing is important because it provides Telomir with the capital needed to advance its lead program into human trials, a critical milestone for any clinical-stage biotech. TNBC is an aggressive form of breast cancer with limited treatment options, and new therapies are urgently needed. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, representing a novel approach that could offer a new avenue for patients with this difficult-to-treat cancer.
For investors, the PIPE financing extends Telomir’s cash runway and validates the company’s strategy, as evidenced by the continued support from a significant shareholder like DeJoria. The absence of warrants and other dilutive instruments may be viewed positively, as it simplifies the capital structure and avoids potential overhang. The FDA’s clearance of the IND application further de-risks the program and allows the company to initiate its first-in-human study, a key value inflection point.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. Its lead program, Telomir-Zn, targets intracellular metal homeostasis and epigenetic regulation. For more details, the full press release is available at https://ibn.fm/0KMpl. The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO. For information about Telomir Pharmaceuticals, visit Telomir Pharmaceuticals (NASDAQ: TELO).
InvestorWire, a specialized communications platform focused on wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. Its services include editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
